President Trump is expected to announce a new $750 million deal with Abbott Laboratories for immediate coVID-19 testing at the Republican National Convention Thursday night, according to a senior White House official. Under the deal, Trump’s management would buy 150 million tests, which will take 15 minutes to produce results.
On Wednesday, the Food and Drug Administration (FDA) granted Abbott approval for emergency use of the check for suspected COVID-19 patients, making it the first immediate check of coronavirus that does not require special computer equipment. The check is the length of a credit card and belongs to the same generation that is used to detect influenza, strep pharyngitis and other infections.
“The effects can be read directly from the verification card, a design similar to some pregnancy controls,” the FDA said in pronouncing its decision. “This undeniable design is fast and effective for healthcare providers and patients and does not require the use of an analyzer.”
The check will only be sold for $5, according to Abbott, which will give you a competitive advantage over similar checks that must be executed on a machine.
“Under President Trump’s leadership, the United States is leading the world in the trials. This is a primary progression that will help our country stay open, bring Americans back to painting and youth to school,” said Alyssa Farah, White House chief strategy officer. Communications. on one to CBS News. “Trump management is proud to work with Abbott Laboratories to make this acquisition imaginable to help the American people.”
This is a primary progression that our country will remain open, make Americans repaint, and young people return to school!
However, Abbott’s new check still has limitations. Like older maximum coronavirus controls, immediate control at all times requires a nasal pattern through a fitness employee and would possibly be less accurate than slower controls. The FDA stated in a ruling that the negative effects of Abbott’s verification might want to be shown through a lab check in some cases.
“In general, antigenic controls are very specific, but they are not as delicate as molecular controls,” according to the FDA. “Due to the threat of a decrease in sensitivity compared to molecular controls, the negative effects of an antigen control should possibly be shown through molecular control before making decisions about the remedy. The negative effects of an antigen control deserve to be taken into account in the context of clinical observations, patient history and epidemiological information.”
Despite its limitations, the Trump administration’s agreement with Abbott may simply increase COVID-19 testing in the United States, a purpose of the public fitness experts the president had rejected a few months earlier.
At an election rally in June, Trump said, “When you test to that point, you’re going to locate more people, you’re going to locate cases. So I said to my other people, ‘Slow down the tests, please.’ They’re testing and testing. We have evidence for other people who don’t know what’s going on.” The president then doubled his comments, contradicting several White House officials who defended his comments by saying they were made in jest.
The Centers for Disease Control and Prevention reviewed its COVID-19 verification recommendations before this week to imply that many others who have been exposed to coronavirus but who have no symptoms may not want to be controlled, prompting the fear of many medical experts because others asymptomatic people can still transmit the virus to others. Dr. Anthony Fauci, the country’s top infectious disease specialist, said he had not commented on the new directions.
“I am involved in interpreting those recommendations and I am involved in this providing other people with the assumption that asymptomatic propagation is not a major concern. In fact, it is,” Fauci said in an interview with CNN on Wednesday.
More than 5800,000 cases of COVID-19 were reported in the United States and more than 180,000 deaths were reported thursday, according to knowledge collected through Johns Hopkins University.
Admiral Brett P. Giroir of the U.S. Department of Health and Human Services (HHS). He said Wednesday that the firm does not expect the new CDC rules to have an effect on the volume of evidence in the United States. In fact, he said the government expects the volume to increase over the next two months as more and more people return to the paintings and school and undergo testing.
According to the FDA, Abbott’s check may be ideal for such controls. In pronouncing the authorization, the FDA indexed “places of care,” such as “the doctor’s office, emergency room, or some schools,” as places where immediate control can be used.
Abbott plans to send “tens of millions” of tests next month and then move on to “50 million tests a month in early October.”
“Given the undeniable nature of this test,” the FDA wrote, “most likely that such evidence is widely available.”
Fin Gómez contributed to this report.